文献速递眼底病与葡萄膜炎

英国数据库研究:玻璃体腔地塞米松植入剂(傲迪适)治疗视网膜静脉阻塞相关黄斑水肿

UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION.
PubMed 文献 · Retina · 2023-01-01

该研究基于16个中心电子病历系统提取的常规匿名数据,评估玻璃体腔地塞米松植入剂治疗视网膜静脉阻塞继发黄斑水肿的治疗模式、视力结局和安全性。真实世界视力结果与临床试验相当;基线存在高眼压或青光眼的眼压升高可通过额外药物治疗控制;有晶状体眼眼压升高可能比人工晶状体眼更常见。

要点

  • 31%(476眼)接受2次注射,11.7%(182眼)和3.7%(58眼)分别接受3次和4次注射。
  • 平均基线Snellen视力从20/125提升至首次注射后20/40。
  • 24个月白内障手术概率为15%;有晶状体眼眼压较基线变化≥10 mmHg的比例为14.2%,高于人工晶状体眼的5.4%(P=0.004)。

核心结论

  • 真实世界中玻璃体腔地塞米松植入剂治疗视网膜静脉阻塞继发黄斑水肿的视力结果与临床试验环境相当。
  • 基线存在高眼压或青光眼的眼,其眼压升高可通过额外药物治疗控制。
  • 玻璃体腔地塞米松植入剂引起的眼压升高在有晶状体眼可能比人工晶状体眼更常见。

研究设计与样本

  • 研究类型为基于常规收集的匿名电子病历数据的多中心研究,从16个中心远程提取最长2年的数据。
  • 1250眼(80.6%)为初治眼;989眼中28%(275眼)在玻璃体腔地塞米松植入剂使用前存在高眼压或正在使用降眼压药物。

主要发现

  • 31%(476眼)接受2次注射,11.7%(182眼)接受3次注射,3.7%(58眼)接受4次注射。
  • 平均基线Snellen视力从20/125提升至首次注射后20/40。
  • 24个月时白内障手术概率为15%。
  • 眼压较基线变化≥10 mmHg的比例在有晶状体眼为14.2%,高于人工晶状体眼的5.4%(P=0.004)。
  • 3眼需行眼压滤过手术(0.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study the treatment patterns, visual outcomes and safety profile of intravitreal dexamethasone implant (IDI) used for the treatment of macular edema secondary to retinal vein occlusion. METHODS: Up to 2 years of routinely collected anonymized data within electronic medical record systems were remotely extracted from 16 centers. The outcome measures include visual outcome, number of injections, and safety measures, including the rate of intraocular pressure (IOP) rise, frequency of IOP-lowering medication usage, and cataract surgery rates. RESULTS: The study included 688 eyes (44.4%) with central retinal vein occlusion and 862 eyes (55.6%) with branch retinal vein occlusion; 1,250 eyes (80.6%) were treatment naive and 28% (275/989) had high IOP or were on IOP-lowering medications before IDI use. It was found that 31% (476) of eyes received two injections, and 11.7% (182) and 3.7% (58) of eyes received three and four injections, respectively. The mean baseline Snellen visual acuity improved from 20/125 to 20/40 after the first injection. The probability of cataract surgery was 15% at 24 months. The proportion of eyes with ≥10 mmHg change from baseline was higher in phakic (14.2%) compared with pseudophakic eyes (5.4%, P = 0.004). Three eyes required IOP filtering surgery (0.2%). CONCLUSION: The visual results of IDI in eyes with macular edema secondary to retinal vein occlusion in the real world are comparable to those of clinical trial setting. Increased IOP in eyes with preexisting ocular hypertension or glaucoma can be controlled with additional medical treatment. Intraocular pressure rise with IDI may be more frequent in phakic than in pseudophakic eyes.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Soliman MK, Zarranz-Ventura J, Chakravarthy U, et al. UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION. Retina. 2023. PMID: 36729561. doi:10.1097/IAE.0000000000003698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。